• Candidate pathogenic germ line variants in TRAF3 and NCOA4 were identified for iMCD occurring in identical twins.

  • Using scRNAseq and Stereo-seq, IL-6 pathway signals were dominant in nodal fibroblastic reticular cells and endothelial cells.

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a rare cytokine-driven disorder characterized by systemic inflammation, generalized lymphadenopathy, and organ dysfunction. Here, we present an unusual occurrence of iMCD in identical twins and examined the immune milieu within the affected lymphoid organs and the host circulation using multiomic high-dimensional profiling. Using spatial enhanced resolution omics sequencing (Stereo-seq) transcriptomic profiling, we performed unsupervised spatially constrained clustering to identify different anatomic structures, mapping the follicles and interfollicular regions. After a cell segmentation approach, interleukin 6 (IL-6) pathway genes significantly colocalized with endothelial cells and fibroblastic reticular cells, confirming observations using a single-cell sequencing approach (10× Chromium). Furthermore, single-cell sequencing of peripheral blood mononuclear cells revealed an “inflammatory” peripheral monocytosis enriched for the expression of S100A family genes in both twins. In summary, we provided evidence of the putative cell-of-origin of IL-6 signals in iMCD and described a distinct monocytic host immune response phenotype through a unique identical twin model.

1.
Fajgenbaum
DC
,
Uldrick
TS
,
Bagg
A
, et al
.
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease
.
Blood
.
2017
;
129
(
12
):
1646
-
1657
.
2.
Carbone
A
,
Borok
M
,
Damania
B
, et al
.
Castleman disease
.
Nat Rev Dis Primers
.
2021
;
7
(
1
):
84
.
3.
Fajgenbaum
DC
,
June
CH
.
Cytokine storm
.
N Engl J Med
.
2020
;
383
(
23
):
2255
-
2273
.
4.
van Rhee
F
,
Wong
RS
,
Munshi
N
, et al
.
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial [published correction appears in Lancet Oncol. 2014;15(10):417]
.
Lancet Oncol
.
2014
;
15
(
9
):
966
-
974
.
5.
Nishimoto
N
,
Kanakura
Y
,
Aozasa
K
, et al
.
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
.
Blood
.
2005
;
106
(
8
):
2627
-
2632
.
6.
Patel
M
,
Ikeda
S
,
Pilat
SR
,
Kurzrock
R
.
JAK1 genomic alteration associated with exceptional response to siltuximab in cutaneous Castleman disease
.
JAMA Dermatol
.
2017
;
153
(
5
):
449
-
452
.
7.
Baker
TS
,
Gambino
KJ
,
Schriefer
L
, et al
.
A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease
.
Blood Adv
.
2018
;
2
(
21
):
2959
-
2963
.
8.
Nagy
A
,
Bhaduri
A
,
Shahmarvand
N
, et al
.
Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas
.
Blood Adv
.
2018
;
2
(
5
):
481
-
491
.
9.
Li
Z
,
Lan
X
,
Li
C
, et al
.
Recurrent PDGFRB mutations in unicentric Castleman disease
.
Leukemia
.
2019
;
33
(
4
):
1035
-
1038
.
10.
You
L
,
Lin
Q
,
Zhao
J
,
Shi
F
,
Young
KH
,
Qian
W
.
Whole-exome sequencing identifies novel somatic alterations associated with outcomes in idiopathic multicentric Castleman disease
.
Br J Haematol
.
2020
;
188
(
5
):
e64
-
e67
.
11.
Yoshimi
A
,
Trippett
TM
,
Zhang
N
, et al
.
Genetic basis for iMCD-TAFRO
.
Oncogene
.
2020
;
39
(
15
):
3218
-
3225
.
12.
Goodman
AM
,
Jeong
AR
,
Phillips
A
, et al
.
Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease
.
Eur J Haematol
.
2021
;
107
(
6
):
642
-
649
.
13.
Endo
Y
,
Koga
T
,
Ubara
Y
,
Sumiyoshi
R
,
Furukawa
K
,
Kawakami
A
.
Mediterranean fever gene variants modify clinical phenotypes of idiopathic multi-centric Castleman disease
.
Clin Exp Immunol
.
2021
;
206
(
1
):
91
-
98
.
14.
van Rhee
F
,
Voorhees
P
,
Dispenzieri
A
, et al
.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
.
Blood
.
2018
;
132
(
20
):
2115
-
2124
.
15.
Rae
W
,
Sowerby
JM
,
Verhoeven
D
, et al
.
Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations
.
Sci Immunol
.
2022
;
7
(
74
):
eabn3800
.
16.
Lin
WW
,
Yi
Z
,
Stunz
LL
,
Maine
CJ
,
Sherman
LA
,
Bishop
GA
.
The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development
.
Sci Signal
.
2015
;
8
(
392
):
ra88
.
17.
Wing
A
,
Xu
J
,
Meng
W
, et al
.
Transcriptome and unique cytokine microenvironment of Castleman disease
.
Mod Pathol
.
2022
;
35
(
4
):
451
-
461
.
18.
Pai
RAL
,
Japp
AS
,
Gonzalez
M
, et al
.
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease
.
JCI Insight
.
2020
;
5
(
9
):
e135031
.
19.
Gonzalez
LL
,
Garrie
K
,
Turner
MD
.
Role of S100 proteins in health and disease
.
Biochim Biophys Acta Mol Cell Res
.
2020
;
1867
(
6
):
118677
.
20.
Villani
AC
,
Satija
R
,
Reynolds
G
, et al
.
Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
.
Science
.
2017
;
356
(
6335
):
eaah4573
.
You do not currently have access to this content.
Sign in via your Institution